Atrial Fibrillation Clinical Trials
A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 463 clinical trials
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
Atrial fibrillation (AF) is a major public health problem. The efficacy of the existing techniques is limited in the more aggressive forms. It is therefore necessary to develop approaches, in particular the identification of relevant biomarkers, to prevent the onset, recurrence or progression of AF in at-risk patients. The objective …
CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation
This feasibility study will be conducted to demonstrate the initial safety and effectiveness of the CellFX® nsPFA™ Cardiac Clamp in performing a box lesion around the 4 pulmonary veins as an isolated procedure or as a part of a more extensive surgical ablation set in conjunction with concomitant cardiac surgical …
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
EdOxaban in fRagIle Patients With Percutaneous Endoscopic GAstrostoMy and atrIal fIbrIllation
The goal of this interventional study is to describe the use of Edoxaban via PEG in patients with an indication to anticoagulation therapy. One arm will receive Edoxaban through PEG and the other arm will receive other Direct oral anticoagulants through PEG or subcutaneous heparin or LMWH. Once enrolled, patients …
Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery
Postoperative atrial fibrillation is a major complication of cardiac surgery, which could lead to high morbidity and mortality, increase duration of hospital stay and increase the cost of treatment. New-onset atrial fibrillation after cardiac surgery is considered as a multifactorial phenomenon. Amiodarone, the most commonly used drug for cardioversion, is …
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)
To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.
Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care …
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural hematoma. The main questions it aims to answer are: Does anticoagulation resumption 5 days after surgery as compared …
Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture
Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause …
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
This study aims to compare the efficacy and safety of the edoxaban and the warfarin in atrial fibrillation patients with mitral stenosis. The study design is a multicenter, randomized, open-label, investigator initiated phase 2 trial. The patients were randomly assigned to Edoxaban or Warfarin groups. Primary outcome was a composite …
